Income Taxes - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) audit	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Income Taxes Disclosure [Line Items]
Capitalized research and development costs	$ 261,400,000
Percentage of stock owned resulting in an ownership change	50.00%
Aggregate period	3 years
Valuation allowance	$ 295,993,000	$ 236,478,000	$ 594,752,000
Increase (decrease) for the current period	59,515,000	(358,274,000)
Accrued interest and penalties related to uncertain tax positions	0	0
Unrecognized tax benefits	$ 26,190,000	24,220,000	$ 21,131,000
Number of federal, state or foreign audits in process | audit	0
U.S.
Income Taxes Disclosure [Line Items]
Capitalized research and development costs, amortization period	5 years
Non-US
Income Taxes Disclosure [Line Items]
Capitalized research and development costs, amortization period	15 years
Prepaid Expenses and Other Current Assets
Income Taxes Disclosure [Line Items]
Income tax receivable	$ 300,000	$ 2,900,000
Federal Orphan Drug Tax Credit
Income Taxes Disclosure [Line Items]
Research and development tax credit	126,500,000
State and Local Jurisdiction
Income Taxes Disclosure [Line Items]
Net operating loss carryforwards	1,200,000,000
State and Local Jurisdiction | Research Tax Credit Carryforward
Income Taxes Disclosure [Line Items]
Research and development tax credit	25,700,000
Foreign Income Tax
Income Taxes Disclosure [Line Items]
Net operating loss carryforwards	65,200,000
Federal | Research Tax Credit Carryforward
Income Taxes Disclosure [Line Items]
Research and development tax credit	$ 16,900,000